Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.

Molecular Cancer Therapeutics
Joanne M MunckNicola J Curtin

Abstract

DNA double-strand breaks (DSB) are the most cytotoxic lesions induced by topoisomerase II poisons. Nonhomologous end joining (NHEJ) is a major pathway for DSB repair and requires DNA-dependent protein kinase (DNA-PK) activity. DNA-PK catalytic subunit (DNA-PKcs) is structurally similar to PI-3K, which promotes cell survival and proliferation and is upregulated in many cancers. KU-0060648 is a dual inhibitor of DNA-PK and PI-3K in vitro. KU-0060648 was investigated in a panel of human breast and colon cancer cells. The compound inhibited cellular DNA-PK autophosphorylation with IC(50) values of 0.019 μmol/L (MCF7 cells) and 0.17 μmol/L (SW620 cells), and PI-3K-mediated AKT phosphorylation with IC(50) values of 0.039 μmol/L (MCF7 cells) and more than 10 μmol/L (SW620 cells). Five-day exposure to 1 μmol/L KU-0060648 inhibited cell proliferation by more than 95% in MCF7 cells but only by 55% in SW620 cells. In clonogenic survival assays, KU-0060648 increased the cytotoxicity of etoposide and doxorubicin across the panel of DNA-PKcs-proficient cells, but not in DNA-PKcs-deficient cells, thus confirming that enhanced cytotoxicity was due to DNA-PK inhibition. In mice bearing SW620 and MCF7 xenografts, concentrations of KU-0060648 tha...Continue Reading

References

Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N R RodriguesD P Lane
Dec 1, 1991·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·G Iliakis
Jun 1, 1990·International Journal of Radiation Biology·J F Ward
Jul 4, 1990·Journal of the National Cancer Institute·P SkehanM R Boyd
Jul 25, 1998·Advances in Genetics·P A Jeggo
Aug 1, 1998·Biochimica Et Biophysica Acta·H ShenK D Tew
Dec 23, 1998·Trends in Cell Biology·R KanaarD C van Gent
Apr 24, 1999·Genes & Development·G C Smith, S P Jackson
Mar 8, 2002·Cellular Signalling·Karleen M Nicholson, Neil G Anderson
May 23, 2002·Carcinogenesis·Stephen P Jackson
Jun 1, 2002·Science·Lewis C Cantley
Jun 18, 2002·International Journal of Radiation Biology·M YoshidaT Ono
Apr 25, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Lasse Tengbjerg HansenMogens Spang-Thomsen
Jun 5, 2003·Breast Cancer Research and Treatment·Nicole ConcinRobert Zeillinger
Aug 5, 2003·Molecular and Cellular Biology·Kai RothkammMarkus Löbrich
Jun 10, 2004·British Journal of Cancer·S BamfordR Wooster
Jan 29, 2005·The Journal of Biological Chemistry·Benjamin P C ChenDavid J Chen
Apr 20, 2006·Journal of the National Cancer Institute·Shin-ichi YaguchiTakao Yamori
Sep 17, 2008·Oncogene·T L Yuan, L C Cantley
Oct 29, 2008·Oncogene·T F Franke
Jan 30, 2009·Cell Cycle·Sandrine GuillardPaul Workman
Dec 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Saskia M BrachmannSauveur-Michel Maira
May 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carol O'BrienMark R Lackner

❮ Previous
Next ❯

Citations

Jun 14, 2013·Science Translational Medicine·Arina RiabinskaHans Christian Reinhardt
Dec 24, 2013·Pharmacology & Therapeutics·Todd M PittsErica L Bradshaw-Pierce
Feb 1, 2013·International Journal of Radiation Biology·Eva NovotnáJiřina Vávrová
May 31, 2015·Vascular Pharmacology·Prasanna Abeyrathna, Yunchao Su
Feb 26, 2013·International Journal of Radiation Oncology, Biology, Physics·Chen Wang, Susan P Lees-Miller
Oct 31, 2012·Pharmacology & Therapeutics·John M Furgason, El Mustapha Bahassi
Dec 9, 2015·Cancer Treatment Reviews·Hylke W WieringaMarcel A T M van Vugt
Feb 21, 2016·Pharmacology & Therapeutics·Navnath S GavandeJohn J Turchi
May 21, 2013·British Journal of Pharmacology·N J Curtin
Feb 4, 2014·Cancer Science·Noriko Hosoya, Kiyoshi Miyagawa
Sep 24, 2013·Investigational New Drugs·Cheree FitzgibbonChristopher Bradley
Aug 27, 2015·Genome Medicine·Francis RobertJerry Pelletier
Aug 26, 2014·Biochemical and Biophysical Research Communications·Hao HuJianping Li
Sep 14, 2016·Progress in Retinal and Eye Research·Mert YanikKnut Stieger
Oct 30, 2016·DNA Repair·Rosa M PascaleDiego F Calvisi
Dec 19, 2016·Biochemical and Biophysical Research Communications·Hao HuYuanLong Gu
Feb 9, 2017·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Jayme Salsman, Graham Dellaire
Apr 20, 2017·ChemMedChem·Suzannah J HarnorCéline Cano
Apr 12, 2018·International Journal of Molecular Sciences·Jolene Michelle HelenaAnne Elisabeth Mercier
Feb 1, 2014·Nature Reviews. Drug Discovery·David A Fruman, Christian Rommel
Nov 24, 2012·Nature Reviews. Cancer·Nicola J Curtin
Sep 22, 2017·Current Medicinal Chemistry·Yinglu LiWei-Guo Zhu
Feb 16, 2018·Current Medicinal Chemistry·Paulina KopaTomasz Poplawski
Oct 4, 2019·The Journal of Clinical Investigation·Catherine E WilloughbyStephen R Wedge
May 18, 2018·Oxidative Medicine and Cellular Longevity·Pierpaola DavalliDomenico D'Arca
Feb 27, 2019·Current Stem Cell Research & Therapy·Eloisi Caldas-LopesMonica L Guzman
Jun 1, 2019·Communications Biology·Yagiz A AksoyDaniel Hesselson

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.